Company intelligence / Profile preview
SanBio
Chuo-ku, Tokyo, Japansanbio.com ↗
- Ownership
- Private
- Employees
- ~29
- Development stage
- Commercial
01
Overview
SanBio develops regenerative cell medicines to restore nerve function lost due to disease or injury. The company recently obtained marketing approval for its SB623 chronic TBI program in Japan. It also received a new patent for cell therapy using SB623 for chronic motor deficit associated with ischemic stroke in the US.
- Therapeutic areas
- OphthalmologyOncologyImmunologyNeurology
- Modalities
- Regenerative cell medicinescell-based therapiesmodified and cultured adult bone marrow-derived mesenchymal stem cells
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on SanBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SanBio.